Former England captain Lewis Moody said he had been "brought in off the bench" as he paid tribute to fellow rugby players ...

The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

The 2025 Research Innovation Grants are supporting projects focused on biomarkers, risk factors, and treatments for ALS.

The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in ...

This valuable study addresses a critical and timely question regarding the role of a subpopulation of cortical interneurons (Chrna2-expressing Martinotti cells) in motor learning and cortical dynamics ...

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...

MIT researchers discovered that the prefrontal cortex doesn’t just send generic control signals—it tailors its messages to ...

Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...

Researchers in Australia have identified a three-drug combination that greatly extends the survival of motor neuron cells in ...

Novartis ( NVS) on Monday said that the U.S. FDA has approved Itvisma for the treatment of children two years and older, ...